Servier, an independent international pharmaceutical group, has agreed to acquire Day One Biopharmaceuticals for $21.50 in cash per share, valuing the company at roughly $2.5 billion in total equity value.
The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions including shareholder tender requirements and U.S. antitrust clearance. The deal represents a premium of about 68% over Day One’s closing price on March 5 and roughly 86% over the one‑month volume‑weighted average price as of that date.
The acquisition expands Servier’s oncology portfolio, particularly in rare pediatric low‑grade glioma, and provides Day One with additional resources and global commercial capabilities to accelerate its growth and pipeline development.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.